Lots of pre-ASH lymphoma news:
Seattle Genetics Leads Roche in Race to Develop Combo Cancer Therapy
Seattle Genetics Inc. and Takeda Pharmaceutical Co. may beat Roche Holding AG in developing a new type of combination cancer therapy that’s less toxic than standard treatments.
52nd ASH Annual Meeting Presentation of Initial Phase II Data from the Saphire Hodgkin’s Lymphoma Trial with Resminostat
Pixantrone Phase III End of Study Results to be Presented at the 52nd Annual Meeting of the American Society of Hematology
A new Phase III Data Analysis for BiovaxID®, Personalized Lymphoma Vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.
Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH
These are only a few of the anti-lymphoma research advances which will be revealed at this weekend’s meetings–and I will be there to share the findings with you!
Note every one of these sites is business related. Let’s not forget these drug trials are all about the money. If a new drugs work, that drug company’s stock soars. The fact patients benefit is almost an afterthought.
But who cares, right? As long as the drugs work–and our insurance companies continue to pick up the tab!
I’m leaving for Orlando in 30 minutes. Hope I find lots of good news for my fellow blood cancer patients and caregivers!
Feel good and keep smiling! Pat